

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. Department of Commerce

		PADEMA		Сотр	lete if Known
Substitute for form 1449A/PTO		Application No.	09/841,744		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	04/24/2001
				First Named Inventor	DiMartino
			ssary)	Art Unit	1653
		Examiner Name	Kam		
Sheet	1	Of	2	Attorney Docket No.	12636.891

	U.S. PATENT DOCUMENTS				
Examiner's Initials		Document No.	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No. 1	Number-Kind Code <sup>2</sup> (if known)		Name of Patentee or Applicant of Cited Document	
	<u> </u>	US-			*
		US-			
		US-			
·		US-			
		US-			
		US-	*		
		US-			
		US-	·	·	
		US-		·	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document				
Examiner's Initials	Cite No.1	Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
CMK		WO 02/069903	09/12/2002	Biocryst Pharmaceuticals, Inc.		
						$\vdash$
			,			H
		*				
EXAMINER				DATE		
SIGNATURE		Ch 2-/-		DATE CONSIDERED	9/0/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINENC Initial if reference considered, whether or not chainon is in conformance with instructions. Draw into incomp chainon in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPBP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

equired t		Approved for use through 10/31/2002. OMB 0651-0  J.S. Palent and Trademark Office: U.S. Department of Communities it contains a valid OMB control number.			
	Complete if Known				
	Application No.	09/841,744			
F	Filing Date	04/24/2001	-1		

## RADEMARY Substitute for form 1449APTO INFORMATION DISCLOSURE

Sheet

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Of

2

Con	aptete ii Known
Application No.	09/841,744
Filing Date	04/24/2001
First Named Inventor	DiMartino
Art Unit	1653
Examiner Name	Kam
Attorney Docket No.	12636.891

		OTHER PRIOR ART – NON PATENT RELATED DOCUMENTS  Include name of suthor (in CAPITAL LETTERS), title of the stricle (when appropriate), title of the	<del></del>
Examiner	Cite	Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	
Initials*	No.1	number(s) publisher city and/or country where published	T2
A.11		SHEIKHNEJAD, G. et al., "Mechanism of inhibition of DNA (cytosine C5)-	
CMK		methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine", J.	
		Mol. Biol., 1999, pages 2021-2034, Vol. 285.	<u> </u>
- 1		GOFFIN, J. et al., "DNA methyltransferase inhibitors—state of the art", Annals of	1
$\perp \perp$		Oncology, 2002, pages 1699-1716, Vol. 13.	<u> </u>
CHK		WIJERMANS, P. et al., "Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients", <i>Journal of Clinical Oncology</i> , March 2000, pages 956-962, Vol. 18, No. 5	
	18	·	
		·	-
	-		<u> </u>
		·	
			_
j			
			<u> </u>
<del></del> -			-
ļ			
			-
EXAMIN IGNATU		CAC DATE CONSIDERED 9/10/04	•

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPBP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.